Incremental Cost-Effectiveness Ratios for Treatment Duration and Heroin Use Outcomes at 6 Months.

The Cost-Effectiveness of Financial Incentives to Achieve Heroin Abstinence in Individuals With Heroin Use Disorder Starting New Treatment Episodes:A Cluster Randomized Trial-Based Economic Evaluation

Shearer, James
Metrebian, Nicola
Weaver, Tim
Goldsmith, Kimberley
Strang, John
Pilling, S
Mitcheson, Luke
Day, Ed
Dunn, John
Glasper, Anthony
Akhtar, Shabana
Bajaria, Jalpa
Charles, Vikki
Desai, Roopal
Haque, Farjana
Little, Nicholas
McKechnie, Hortencia
Mosler, Franziska
Mutz, Julian
Poovendran, Dilkushi
Byford, Sarah

May 2023

Objectives: Cost-effectiveness analysis of two 12-week contingency management (CM) schedules targeti...

Cost-effectiveness plane in incremental number of treatment success and incremental cost.

Mari Kajiwara Saito (5987981)
Christopher M. Parry (349451)
Shunmay Yeung (53391)

December 2018

Cost-effectiveness plane in incremental number of treatment success and incremental cost.</p

Incremental cost effectiveness ratio plan, presenting the results of the probabilistic sensitivity analysis of LPV/r vs. ATV+r 1 regimens.

Emanuela Foglia (383172)
Paolo Bonfanti (383173)
Giuliano Rizzardini (103636)
Erminio Bonizzoni (383174)
Umberto Restelli (383175)
Elena Ricci (316160)
Emanuele Porazzi (383176)
Francesca Scolari (127986)
Davide Croce (383177)

February 2013

Incremental cost effectiveness ratio plan, presenting the results of the probabilistic sensitivit...

Incremental Cost-Effectiveness Analyses of Heroin Use, Medical Treatment, and Work-Related Outcomes at 6 Months from Baseline.

Jennifer Prah Ruger (116433)
Marek Chawarski (116436)
Mahmud Mazlan (116439)
Nora Ng (116442)
Richard Schottenfeld (116446)

December 2012

Abbreviations: D, dominated; Nalt, Naltrexone; Bup, Buprenorphine.*The total number of res...

Cost effectiveness ratio and incremental cost effectiveness ratio analysis per year and period considering the cost of embedded pharmaceutical care in the cost of the public health system with assistance to hypertensive patients.

Maurílio de Souza Cazarim (2838158)
Leonardo Régis Leira Pereira (492901)

March 2018

Cost effectiveness ratio and incremental cost effectiveness ratio analysis per year and period co...

Mean and median incremental cost-effectiveness ratios (cost per DALY averted) with parameters varied, by age group and vial size (US$).

Ashraful Islam Khan (236188)
Ann Levin (361456)
Dennis L. Chao (119857)
Denise DeRoeck (5832239)
Dobromir T. Dimitrov (669490)
Jahangir A. M. Khan (632407)
Muhammad Shariful Islam (5832242)
Mohammad Ali (73095)
Md. Taufiqul Islam (5832245)
Abdur Razzaque Sarker (2167912)
John D. Clemens (148728)
Firdausi Qadri (89170)

October 2018

Mean and median incremental cost-effectiveness ratios (cost per DALY averted) with parameters varied...

Incremental Cost-Effectiveness Ratio (ICER) according to different treatment completion rates in DOT facilities.

Ricardo Steffen (359737)
Dick Menzies (66118)
Olivia Oxlade (66115)
Marcia Pinto (5653372)
Analia Zuleika de Castro (359738)
Paula Monteiro (359739)
Anete Trajman (359740)

February 2013

The incremental cost-effectiveness ratio was calculated according to an increasing treatment comp...

The Cost-Effectiveness of Financial Incentives to Achieve Heroin Abstinence in Individuals With Heroin Use Disorder Starting New Treatment Episodes:A Cluster Randomized Trial-Based Economic Evaluation

Shearer, James
Metrebian, Nicola
Weaver, Tim
Goldsmith, Kimberley
Strang, John
Pilling, S
Mitcheson, Luke
Day, Ed
Dunn, John
Glasper, Anthony
Akhtar, Shabana
Bajaria, Jalpa
Charles, Vikki
Desai, Roopal
Haque, Farjana
Little, Nicholas
McKechnie, Hortencia
Mosler, Franziska
Mutz, Julian
Poovendran, Dilkushi
Byford, Sarah

May 2023

Objectives: Cost-effectiveness analysis of two 12-week contingency management (CM) schedules targeti...

The Cost-Effectiveness of Financial Incentives to Achieve Heroin Abstinence in Individuals With Heroin Use Disorder Starting New Treatment Episodes:A Cluster Randomized Trial-Based Economic Evaluation

Shearer, James
Metrebian, Nicola
Weaver, Tim
Goldsmith, Kimberley
Strang, John
Pilling, Stephen
Mitcheson, Luke
Day, Ed
Dunn, John
Glasper, Anthony
Akhtar, Shabana
Bajaria, Jalpa
Charles, Vikki
Desai, Roopal
Haque, Farjana
Little, Nicholas
McKechnie, Hortencia
Mosler, Franziska
Mutz, Julian
Poovendran, Dilkushi
Byford, Sarah

May 2023

Objectives: Cost-effectiveness analysis of two 12-week contingency management (CM) schedules targeti...

The Cost-Effectiveness of Financial Incentives to Achieve Heroin Abstinence in Individuals With Heroin Use Disorder Starting New Treatment Episodes:A Cluster Randomized Trial-Based Economic Evaluation

Shearer, James
Metrebian, Nicola
Weaver, Tim
Goldsmith, Kimberley
Strang, John
Pilling, Stephen
Mitcheson, Luke
Day, Ed
Dunn, John
Glasper, Anthony
Akhtar, Shabana
Bajaria, Jalpa
Charles, Vikki
Desai, Roopal
Haque, Farjana
Little, Nicholas
McKechnie, Hortencia
Mosler, Franziska
Mutz, Julian
Poovendran, Dilkushi
Byford, Sarah

May 2023

Objectives: Cost-effectiveness analysis of two 12-week contingency management (CM) schedules targeti...

Incremental cost-effectiveness ratio in increasing order of total infection averted.

Folashade B. Agusto (3663010)
Ibrahim M. ELmojtaba (3719848)

February 2017

Incremental cost-effectiveness ratio in increasing order of total infection averted.</p

The Cost-Effectiveness of Financial Incentives to Achieve Heroin Abstinence in Individuals With Heroin Use Disorder Starting New Treatment Episodes:A Cluster Randomized Trial-Based Economic Evaluation

Shearer, James
Metrebian, Nicola
Weaver, Tim
Goldsmith, Kimberley
Strang, John
Pilling, Stephen
Mitcheson, Luke
Day, Ed
Dunn, John
Glasper, Anthony
Akhtar, Shabana
Bajaria, Jalpa
Charles, Vikki
Desai, Roopal
Haque, Farjana
Little, Nicholas
McKechnie, Hortencia
Mosler, Franziska
Mutz, Julian
Poovendran, Dilkushi
Byford, Sarah

May 2023

Objectives: Cost-effectiveness analysis of two 12-week contingency management (CM) schedules targeti...

Incremental cost-effectiveness ratio for improved IMCI quality of care in a simulated cohort of 1000 patients.

Anatole Manzi (4971760)
Jean Claude Mugunga (4971763)
Hari S. Iyer (451186)
Hema Magge (4595944)
Fulgence Nkikabahizi (4595953)
Lisa R. Hirschhorn (158274)

March 2018

Incremental cost-effectiveness ratio for improved IMCI quality of care in a simulated cohort of 1...

The Cost-Effectiveness of Financial Incentives to Achieve Heroin Abstinence in Individuals With Heroin Use Disorder Starting New Treatment Episodes:A Cluster Randomized Trial-Based Economic Evaluation

Shearer, James
Metrebian, Nicola
Weaver, Tim
Goldsmith, Kimberley
Strang, John
Pilling, Stephen
Mitcheson, Luke
Day, Ed
Dunn, John
Glasper, Anthony
Akhtar, Shabana
Bajaria, Jalpa
Charles, Vikki
Desai, Roopal
Haque, Farjana
Little, Nicholas
McKechnie, Hortencia
Mosler, Franziska
Mutz, Julian
Poovendran, Dilkushi
Byford, Sarah

May 2023

Objectives: Cost-effectiveness analysis of two 12-week contingency management (CM) schedules targeti...

Incremental cost-effectiveness ratio in increasing order of total infection averted.

Folashade B. Agusto (3663010)
Ibrahim M. ELmojtaba (3719848)

February 2017

Incremental cost-effectiveness ratio in increasing order of total infection averted.</p

The Cost-Effectiveness of Financial Incentives to Achieve Heroin Abstinence in Individuals With Heroin Use Disorder Starting New Treatment Episodes:A Cluster Randomized Trial-Based Economic Evaluation

Shearer, James
Metrebian, Nicola
Weaver, Tim
Goldsmith, Kimberley
Strang, John
Pilling, S
Mitcheson, Luke
Day, Ed
Dunn, John
Glasper, Anthony
Akhtar, Shabana
Bajaria, Jalpa
Charles, Vikki
Desai, Roopal
Haque, Farjana
Little, Nicholas
McKechnie, Hortencia
Mosler, Franziska
Mutz, Julian
Poovendran, Dilkushi
Byford, Sarah

May 2023

Objectives: Cost-effectiveness analysis of two 12-week contingency management (CM) schedules targeti...

Cost-effectiveness plane in incremental number of treatment success and incremental cost.

Mari Kajiwara Saito (5987981)
Christopher M. Parry (349451)
Shunmay Yeung (53391)

December 2018

Cost-effectiveness plane in incremental number of treatment success and incremental cost.</p

Incremental cost effectiveness ratio plan, presenting the results of the probabilistic sensitivity analysis of LPV/r vs. ATV+r 1 regimens.

Emanuela Foglia (383172)
Paolo Bonfanti (383173)
Giuliano Rizzardini (103636)
Erminio Bonizzoni (383174)
Umberto Restelli (383175)
Elena Ricci (316160)
Emanuele Porazzi (383176)
Francesca Scolari (127986)
Davide Croce (383177)

February 2013

Incremental cost effectiveness ratio plan, presenting the results of the probabilistic sensitivit...

Incremental Cost-Effectiveness Analyses of Heroin Use, Medical Treatment, and Work-Related Outcomes at 6 Months from Baseline.

Jennifer Prah Ruger (116433)
Marek Chawarski (116436)
Mahmud Mazlan (116439)
Nora Ng (116442)
Richard Schottenfeld (116446)

December 2012

Abbreviations: D, dominated; Nalt, Naltrexone; Bup, Buprenorphine.*The total number of res...

Cost effectiveness ratio and incremental cost effectiveness ratio analysis per year and period considering the cost of embedded pharmaceutical care in the cost of the public health system with assistance to hypertensive patients.

Maurílio de Souza Cazarim (2838158)
Leonardo Régis Leira Pereira (492901)

March 2018

Cost effectiveness ratio and incremental cost effectiveness ratio analysis per year and period co...

Mean and median incremental cost-effectiveness ratios (cost per DALY averted) with parameters varied, by age group and vial size (US$).

Ashraful Islam Khan (236188)
Ann Levin (361456)
Dennis L. Chao (119857)
Denise DeRoeck (5832239)
Dobromir T. Dimitrov (669490)
Jahangir A. M. Khan (632407)
Muhammad Shariful Islam (5832242)
Mohammad Ali (73095)
Md. Taufiqul Islam (5832245)
Abdur Razzaque Sarker (2167912)
John D. Clemens (148728)
Firdausi Qadri (89170)

October 2018

Mean and median incremental cost-effectiveness ratios (cost per DALY averted) with parameters varied...

Incremental Cost-Effectiveness Ratio (ICER) according to different treatment completion rates in DOT facilities.

Ricardo Steffen (359737)
Dick Menzies (66118)
Olivia Oxlade (66115)
Marcia Pinto (5653372)
Analia Zuleika de Castro (359738)
Paula Monteiro (359739)
Anete Trajman (359740)

February 2013

The incremental cost-effectiveness ratio was calculated according to an increasing treatment comp...

The Cost-Effectiveness of Financial Incentives to Achieve Heroin Abstinence in Individuals With Heroin Use Disorder Starting New Treatment Episodes:A Cluster Randomized Trial-Based Economic Evaluation

Shearer, James
Metrebian, Nicola
Weaver, Tim
Goldsmith, Kimberley
Strang, John
Pilling, S
Mitcheson, Luke
Day, Ed
Dunn, John
Glasper, Anthony
Akhtar, Shabana
Bajaria, Jalpa
Charles, Vikki
Desai, Roopal
Haque, Farjana
Little, Nicholas
McKechnie, Hortencia
Mosler, Franziska
Mutz, Julian
Poovendran, Dilkushi
Byford, Sarah

May 2023

Objectives: Cost-effectiveness analysis of two 12-week contingency management (CM) schedules targeti...

The Cost-Effectiveness of Financial Incentives to Achieve Heroin Abstinence in Individuals With Heroin Use Disorder Starting New Treatment Episodes:A Cluster Randomized Trial-Based Economic Evaluation

Shearer, James
Metrebian, Nicola
Weaver, Tim
Goldsmith, Kimberley
Strang, John
Pilling, Stephen
Mitcheson, Luke
Day, Ed
Dunn, John
Glasper, Anthony
Akhtar, Shabana
Bajaria, Jalpa
Charles, Vikki
Desai, Roopal
Haque, Farjana
Little, Nicholas
McKechnie, Hortencia
Mosler, Franziska
Mutz, Julian
Poovendran, Dilkushi
Byford, Sarah

May 2023

Objectives: Cost-effectiveness analysis of two 12-week contingency management (CM) schedules targeti...

The Cost-Effectiveness of Financial Incentives to Achieve Heroin Abstinence in Individuals With Heroin Use Disorder Starting New Treatment Episodes:A Cluster Randomized Trial-Based Economic Evaluation

Shearer, James
Metrebian, Nicola
Weaver, Tim
Goldsmith, Kimberley
Strang, John
Pilling, Stephen
Mitcheson, Luke
Day, Ed
Dunn, John
Glasper, Anthony
Akhtar, Shabana
Bajaria, Jalpa
Charles, Vikki
Desai, Roopal
Haque, Farjana
Little, Nicholas
McKechnie, Hortencia
Mosler, Franziska
Mutz, Julian
Poovendran, Dilkushi
Byford, Sarah

May 2023

Objectives: Cost-effectiveness analysis of two 12-week contingency management (CM) schedules targeti...

Incremental cost-effectiveness ratio in increasing order of total infection averted.

Folashade B. Agusto (3663010)
Ibrahim M. ELmojtaba (3719848)

February 2017

Incremental cost-effectiveness ratio in increasing order of total infection averted.</p

The Cost-Effectiveness of Financial Incentives to Achieve Heroin Abstinence in Individuals With Heroin Use Disorder Starting New Treatment Episodes:A Cluster Randomized Trial-Based Economic Evaluation

Shearer, James
Metrebian, Nicola
Weaver, Tim
Goldsmith, Kimberley
Strang, John
Pilling, Stephen
Mitcheson, Luke
Day, Ed
Dunn, John
Glasper, Anthony
Akhtar, Shabana
Bajaria, Jalpa
Charles, Vikki
Desai, Roopal
Haque, Farjana
Little, Nicholas
McKechnie, Hortencia
Mosler, Franziska
Mutz, Julian
Poovendran, Dilkushi
Byford, Sarah

May 2023

Objectives: Cost-effectiveness analysis of two 12-week contingency management (CM) schedules targeti...

Incremental cost-effectiveness ratio for improved IMCI quality of care in a simulated cohort of 1000 patients.

Anatole Manzi (4971760)
Jean Claude Mugunga (4971763)
Hari S. Iyer (451186)
Hema Magge (4595944)
Fulgence Nkikabahizi (4595953)
Lisa R. Hirschhorn (158274)

March 2018

Incremental cost-effectiveness ratio for improved IMCI quality of care in a simulated cohort of 1...

The Cost-Effectiveness of Financial Incentives to Achieve Heroin Abstinence in Individuals With Heroin Use Disorder Starting New Treatment Episodes:A Cluster Randomized Trial-Based Economic Evaluation

Shearer, James
Metrebian, Nicola
Weaver, Tim
Goldsmith, Kimberley
Strang, John
Pilling, Stephen
Mitcheson, Luke
Day, Ed
Dunn, John
Glasper, Anthony
Akhtar, Shabana
Bajaria, Jalpa
Charles, Vikki
Desai, Roopal
Haque, Farjana
Little, Nicholas
McKechnie, Hortencia
Mosler, Franziska
Mutz, Julian
Poovendran, Dilkushi
Byford, Sarah

May 2023

Objectives: Cost-effectiveness analysis of two 12-week contingency management (CM) schedules targeti...

Incremental cost-effectiveness ratio in increasing order of total infection averted.

Folashade B. Agusto (3663010)
Ibrahim M. ELmojtaba (3719848)

February 2017

Incremental cost-effectiveness ratio in increasing order of total infection averted.</p

The Cost-Effectiveness of Financial Incentives to Achieve Heroin Abstinence in Individuals With Heroin Use Disorder Starting New Treatment Episodes:A Cluster Randomized Trial-Based Economic Evaluation

Shearer, James
Metrebian, Nicola
Weaver, Tim
Goldsmith, Kimberley
Strang, John
Pilling, S
Mitcheson, Luke
Day, Ed
Dunn, John
Glasper, Anthony
Akhtar, Shabana
Bajaria, Jalpa
Charles, Vikki
Desai, Roopal
Haque, Farjana
Little, Nicholas
McKechnie, Hortencia
Mosler, Franziska
Mutz, Julian
Poovendran, Dilkushi
Byford, Sarah

May 2023

Objectives: Cost-effectiveness analysis of two 12-week contingency management (CM) schedules targeti...

Cost-effectiveness plane in incremental number of treatment success and incremental cost.

Mari Kajiwara Saito (5987981)
Christopher M. Parry (349451)
Shunmay Yeung (53391)

December 2018

Cost-effectiveness plane in incremental number of treatment success and incremental cost.</p

Incremental cost effectiveness ratio plan, presenting the results of the probabilistic sensitivity analysis of LPV/r vs. ATV+r 1 regimens.

Emanuela Foglia (383172)
Paolo Bonfanti (383173)
Giuliano Rizzardini (103636)
Erminio Bonizzoni (383174)
Umberto Restelli (383175)
Elena Ricci (316160)
Emanuele Porazzi (383176)
Francesca Scolari (127986)
Davide Croce (383177)

February 2013

Incremental cost effectiveness ratio plan, presenting the results of the probabilistic sensitivit...

Incremental Cost-Effectiveness Ratios for Treatment Duration and Heroin Use Outcomes at 6 Months.

Abstract

Extracted data

Incremental Cost-Effectiveness Ratios for Treatment Duration and Heroin Use Outcomes at 6 Months.

Abstract

Extracted data

Related items

Related items